- Home
- REVBW vs LTH Comparison
REVBW vs LTH Comparison
Compare REVBW & LTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- LTH
- Stock Information
- Founded
- REVBW N/A
- LTH 1992
- Country
- REVBW United States
- LTH United States
- Employees
- REVBW 9
- LTH N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- LTH Hotels/Resorts
- Sector
- REVBW Health Care
- LTH Consumer Discretionary
- Exchange
- REVBW Nasdaq
- LTH Nasdaq
- Market Cap
- REVBW N/A
- LTH N/A
- IPO Year
- REVBW 2020
- LTH 2021
- Fundamental
- Price
- REVBW $0.01
- LTH $23.28
- Analyst Decision
- REVBW
- LTH Buy
- Analyst Count
- REVBW 0
- LTH 11
- Target Price
- REVBW N/A
- LTH $26.91
- AVG Volume (30 Days)
- REVBW N/A
- LTH 1.0M
- Earning Date
- REVBW N/A
- LTH 10-24-2024
- Dividend Yield
- REVBW N/A
- LTH N/A
- EPS Growth
- REVBW N/A
- LTH 106.19
- EPS
- REVBW N/A
- LTH 0.68
- Revenue
- REVBW N/A
- LTH $2,516,546,000.00
- Revenue This Year
- REVBW N/A
- LTH $18.52
- Revenue Next Year
- REVBW N/A
- LTH $10.16
- P/E Ratio
- REVBW N/A
- LTH $34.36
- Revenue Growth
- REVBW N/A
- LTH 18.12
- 52 Week Low
- REVBW N/A
- LTH $11.89
- 52 Week High
- REVBW N/A
- LTH $27.12
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- LTH 41.66
- Support Level
- REVBW N/A
- LTH $22.67
- Resistance Level
- REVBW N/A
- LTH $24.81
- Average True Range (ATR)
- REVBW 0.00
- LTH 0.55
- MACD
- REVBW 0.00
- LTH -0.10
- Stochastic Oscillator
- REVBW 0.00
- LTH 19.64
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).